• 1
    Wu A, Buhler LH, Cooper DK. ABO-incompatible organ and bone marrow transplantation: current status. Transpl Int 2003; 16: 2919.
  • 2
    Pierson RN 3rd, Loyd JE, Goodwin A et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002; 74: 7984.
  • 3
    Cooper DK. Clinical survey of heart transplantation between ABO blood group-incompatible recipients and donors. J Heart Transplant 1990; 9: 376381.
  • 4
    Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 12071210.
  • 5
    Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70: 13311335.
  • 6
    Campion EW. A death at Duke. N Engl J Med 2003; 348: 10831084.
  • 7
    Banner NR, Lyster H. Pharmacological Immunosuppression. In: BannerNR, PolakJM, YacoubMH, eds. Lung Transplantation. Cambridge : Cambridge University Press, 2003: 205242.
  • 8
    Reisaeter AV, Leivestad T, Albrechtsen D et al. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation 1995; 60: 242248.
  • 9
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 10
    Kroshus TJ, Dalmasso AP, Leventhal JR, John R, Matas AJ, Bolman RM 3rd. Antibody removal by column immunoabsorption prevents tissue injury in an ex vivo model of pig-to-human xenograft hyperacute rejection. J Surg Res 1995; 59: 4350.
  • 11
    Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800805.
  • 12
    Itescu S, Burke E, Lietz K et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 12141219.
  • 13
    Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282285.
  • 14
    Bonnefoy-Berard N, Genestier L, Flacher M et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 1994; 83: 10511059.
  • 15
    Alkhunaizi AM, De Mattos AM, Barry JM, Bennett WM, Norman DJ. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67: 13191324.
  • 16
    Agishi T, Takahashi K, Yagisawa T, Ota K. Immunoadsorption of anti-A or anti-B antibody for successful kidney transplantation between ABO incompatible pairs and its limitation. Japanese Biosynsorb Research Group. ASAIO Trans 1991; 37: M496M498.
  • 17
    Matic G, Hofmann D, Winkler R et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000; 24: 103107.
  • 18
    Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73: 366368.
  • 19
    Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Bio Drugs 2002; 16: 4755.
  • 20
    John R, Lietz K, Burke E et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II22935.
  • 21
    Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225232.
  • 22
    Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002; 74: 12401242.
  • 23
    West LJ, Pollock-Barziv SM, Dipchand AI et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001; 344: 793800.
  • 24
    Soares MP, Lin Y, Sato K, Stuhlmeier KM, Bach FH. Accommodation. Immunol Today 1999; 20: 434437.
  • 25
    Starnes VA, Barr ML, Cohen RG et al. Living-donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg 1996; 112: 12841290.